Adherence to Antiretroviral Therapy Predicts Time to Viral Load Suppression for Adults with HIV in Ethiopia
For people living with HIV (PLHIV), getting their viral load suppressed quickly on antiretroviral therapy (ART) is key to staying healthy. New research from Arba Minch General Hospital in Ethiopia shows just how much a simple act—taking medication as prescribed—can speed this process.
Led by Sultan Hussen of Arba Minch University’s College of Medicine & Health Sciences, the 2019 study (published in the Chinese Medical Journal) followed 152 adults newly diagnosed with HIV (who had never taken ART before) for six months. The team used the World Health Organization (WHO) standard for viral load suppression—fewer than 1000 HIV RNA copies per milliliter of blood—to measure success.
Blood samples for CD4 counts (a marker of immune health) and viral load were collected by trained staff using standard venipuncture protocols. Viral load testing used the Amplicor Monitor Assay (version 1.5) from Roche Molecular Systems, a reliable method recommended by WHO for low- and middle-income countries (LMICs).
The results were striking: the median time to viral load suppression was three months (95% confidence interval: 2.68–3.32 months). But adherence to ART made the biggest difference: patients who took their medication consistently were 2.6 times more likely to achieve suppression early compared to those with poor adherence (adjusted hazard ratio [AHR] = 2.648, 95% CI: 1.202–5.834, p = 0.016). That means sticking to ART cut the time to better health nearly in half for many.
Supportive treatments also played a role. Patients on cotrimoxazole preventive therapy (CPT) or isoniazid preventive therapy (IPT)—which reduce serious bacterial infections and tuberculosis (TB) risk—suppressed viral load faster. TB is a major threat to PLHIV because it depletes CD4 cells (the immune cells HIV targets) and drives up viral load. Preventing TB co-infection, the researchers note, clears the way for quicker suppression.
Two other factors mattered: baseline CD4 count and initial viral load. Patients with a CD4 count of 200 cells/mm³ or higher (a stronger immune system) suppressed viral load faster than those with lower counts. And PLHIV who started ART with a viral load below 10,000 copies/mL saw results sooner than those with higher initial levels—consistent with findings from Brazil and other countries.
The team’s takeaway? To speed viral load suppression, HIV programs need to: 1) Make routine viral load and CD4 testing available to all ART patients from day one; 2) Strengthen adherence counseling and monitoring; 3) Give extra support to patients at high risk—like those with poor adherence, low CD4 counts, or high baseline viral loads. “Healthcare providers must stay close to these patients,” the researchers write, “and double down on help for those who need it most.”
Readers should keep the study’s limits in mind: data came from just one hospital, so results may not apply to all PLHIV in Ethiopia. The six-month follow-up was also shorter than some studies, so findings are cautious.
For PLHIV and the teams supporting them, the message is clear: adherence isn’t just about following rules—it’s about taking control of health. By prioritizing medication support and regular testing, programs can help more people reach viral suppression faster—and live longer, healthier lives.
The study, “Adherence level to antiretroviral therapy predict the time to viral load suppression of adult people living with HIV on antiretroviral therapy in Arba Minch general hospital,” was published in Chinese Medical Journal (2019; 132: 2891–2892). The full study is available via doi.org/10.1097/CM9.0000000000000519.
Was this helpful?
0 / 0